Skip to main content
Springer logoLink to Springer
. 2026 Nov 9;34(12):1215. doi: 10.1007/s00520-026-11348-9

Impact of nipple–areola complex micropigmentation on quality of life, body image, and sexuality among women after mastectomy: a mixed-methods study

Marina Gómez-Esteban 1,2,✉, Carla Pérez-Ingidua 1,2,3, Paula López-Porras 1,2, Ana Ascaso-del-Río 1,2,4, Verónica Gimeno-Hernán 1,2,3, Ana Belén Rivas-Paterna 1,2,3
PMCID: PMC13748039  PMID: 43004008

Abstract

Purpose

To evaluate changes in quality of life, body image, and sexual well-being following nipple–areola complex micropigmentation in women who had undergone mastectomy and breast reconstruction.

Methods

A mixed-methods study with a pre–post, analytical, longitudinal, and prospective design was conducted in a final sample of 18 women who had undergone mastectomy and subsequent breast reconstruction. Quantitative data were collected using validated quality-of-life questionnaires administered before and after micropigmentation. Qualitative data were collected using a structured questionnaire with 13 open-ended questions and analysed using thematic analysis.

Results

Significant pre–post changes were observed in global health status, emotional functioning, and body image, together with changes in sexuality-related dimensions. Qualitative findings described improvements in body perception, emotional well-being, confidence, and comfort in intimate and social contexts. Participants also identified informational, geographical, economic, and emotional barriers to accessing the procedure.

Conclusion

Quantitative and qualitative findings showed convergent changes in quality of life, body image, emotional well-being, and sexual well-being following nipple–areola complex micropigmentation. However, the uncontrolled single-group pre–post design does not allow causal inference. Further comparative studies with larger samples, longer follow-up, and greater population diversity are needed to strengthen the evidence regarding the effectiveness and longer-term impact of nipple–areola complex micropigmentation.

Keywords: Breast neoplasms, Micropigmentation, Self-concept, Body image, Quality of life, Sexuality

Introduction

Breast cancer is the most frequently diagnosed cancer in women worldwide and represents a major public health problem. According to the World Health Organization, more than 2.3 million women were diagnosed with breast cancer in 2022, with approximately 670,000 deaths attributable to this disease [1]. Although breast cancer remains highly prevalent, advances in early detection and multimodal treatment have substantially improved survival, particularly in high-income countries. This increase in survival has transformed breast cancer into a long-term survivorship condition, highlighting the need to address its long-term physical, psychological, and psychosocial consequences [2–4].

Although survival has improved, patients undergoing surgical treatments such as mastectomy experience significant impacts on their quality of life. Breast loss directly affects body image, leading to alterations in self-image, self-esteem, and perceptions of femininity [5]. These changes are not only aesthetic but also emotional and psychological, potentially contributing to the development of anxiety, depression, and difficulties in adapting to the new life situation [6]. Likewise, sexuality is frequently affected, with changes in sexual desire, intimacy, and confidence in interpersonal relationships [7–9].

Within the recovery process, breast reconstruction plays an important role in improving the quality of life of women who have undergone mastectomy. In this context, nipple–areola complex (NAC) reconstruction, including dermopigmentation, has been associated with improved patient satisfaction and aesthetic outcomes [10]. NAC micropigmentation is an onco-aesthetic technique that allows the semi-permanent recreation of the appearance of the areola and nipple through the implantation of pigments into the superficial layers of the skin, contributing to a more natural appearance of the reconstructed breast and facilitating acceptance of the new body [11, 12].

While this technique may offer potential benefits, in patients with breast cancer—where body image and sexuality are crucial aspects of quality of life—scientific evidence regarding its specific impact on these dimensions remains limited [13]. Most available studies focus on breast reconstruction in general, with limited in-depth analysis of the specific role of NAC micropigmentation, and overall low methodological quality in this field [12]. Furthermore, sexuality remains an insufficiently addressed aspect in oncology care, despite its relevance to patients’ overall well-being [14]. This lack of evidence represents an important knowledge gap in the field of supportive care.

In this context, the aim of this study was to evaluate changes in quality of life, body image, and sexual well-being following nipple–areola complex micropigmentation in women with breast cancer who had undergone mastectomy and breast reconstruction, and to explore their experiences and perceived barriers to accessing the procedure.

Methods

Study design

A mixed-methods study was conducted, integrating both quantitative and qualitative approaches. The quantitative phase was designed as an analytical, longitudinal, prospective study with a single-group pre-post intervention design. The qualitative phase adopted an exploratory-descriptive design based on data collection through a post-intervention questionnaire with open-ended questions. This approach allowed for a comprehensive understanding of the impact of nipple–areola complex micropigmentation, combining objective measures with participants’ subjective experiences.

Study setting

The study was conducted at Hospital Clínico San Carlos, Madrid, Spain, between December 2024 and June 2025.

Participants

The study population consisted of adult women diagnosed with breast cancer who had undergone mastectomy followed by breast reconstruction and were placed on the waiting list for nipple–areola complex micropigmentation at the Hospital Clínico San Carlos (Madrid).

Inclusion criteria were: age ≥ 18 years, previous diagnosis of breast cancer treated with mastectomy and reconstruction, being on the waiting list for micropigmentation, ability to understand and complete questionnaires in Spanish, and signed informed consent. Participants who modified their oncological treatment during the study, presented severe psychiatric disorders, or did not provide informed consent were excluded.

Participant identification and recruitment

Participants were identified at the Hospital Clínico San during follow-up consultations in Oncology and Breast Surgery for breast cancer. Eligible women were identified by the oncology team according to the predefined inclusion and exclusion criteria, including having undergone mastectomy with breast reconstruction and being on the waiting list for nipple–areola complex micropigmentation. Eligible patients were informed individually about the study objectives, procedures, and voluntary nature of participation, and written informed consent was obtained before study participation.

Timing of evaluations

Baseline assessments were performed during the pre-micropigmentation assessment visit, before the procedure. At this visit, participants completed the EORTC QLQ-C30 and EORTC QLQ-BR42 questionnaires to establish baseline measures of quality of life and sexuality. Following micropigmentation, participants completed the same questionnaires at the clinical follow-up visit scheduled 2–4 weeks after the procedure, together with the post-intervention qualitative questionnaire exploring their experiences and perceived barriers to accessing micropigmentation.

Nipple–areola complex micropigmentation procedure

Nipple–areola complex micropigmentation was performed at Hospital Clínico San Carlos in the breast cancer consultation by a specialised aesthetic nurse with expertise in micropigmentation. The procedure consisted of two sessions: an initial micropigmentation session followed by a second session for touch-up and refinement of the result. Topical anaesthetic cream was used to improve patient comfort during the procedure. The duration of each session varied between patients according to individual procedural needs. The micropigmentation was performed using a standard micropigmentation technique.

Micropigmentation was performed only after the breast tissue and surgical scars resulting from breast reconstruction had completely healed. No fixed minimum interval between breast reconstruction and micropigmentation was established or systematically recorded. The procedure was provided within the breast cancer care setting during the early implementation of the hospital’s micropigmentation consultation service.

Quantitative measures

Quality of life and sexuality were assessed using the validated EORTC QLQ-C30 and EORTC QLQ-BR42 questionnaires [18, 19]. The former evaluates dimensions such as physical, emotional, social, and cognitive functioning, as well as global quality of life and cancer-related symptoms. The latter is specifically designed for breast cancer and includes subscales related to body image, sexual function, sexual enjoyment, and specific symptoms.

The analysis was considered bidirectional, recognising both potential improvements and deteriorations across the studied dimensions. It should be noted that subscales were not aggregated, as they represent independent dimensions of quality of life and sexuality. The EORTC does not provide a global index score combining subscales; therefore, results were interpreted individually, respecting the specific nature of each construct.

Scores were linearly transformed to a standardised 0–100 scale according to the EORTC scoring manual, ensuring comparability across subscales. In this format, higher scores indicate better functioning in functional domains and greater symptom burden in symptom scales. Each subscale was analysed independently [20]. Sociodemographic and clinical variables, including age, partner status, and time since mastectomy, were collected for descriptive purposes.

Qualitative data collection

A structured qualitative questionnaire with 13 open-ended questions was designed. Responses were collected after the intervention. This instrument allowed an in-depth exploration of experiences associated with micropigmentation, including motivations for undergoing the procedure, emotions experienced before, during, and after the intervention, perceptions of aesthetic and emotional outcomes, potential barriers to access, and recommendations and overall evaluation of the experience.

Data were collected in written form, voluntarily and anonymously, ensuring participant confidentiality. The aim was to deepen understanding of the subjective experience and complement the quantitative findings.

Data analysis

Quantitative analysis

Quantitative analysis was performed using IBM SPSS Statistics version 29.0 (IBM Corp., Armonk, NY, USA) [21]. Descriptive statistics were calculated for all study variables, using mean and standard deviation for continuous variables and frequencies and percentages for categorical variables.

EORTC QLQ-C30 and QLQ-BR42 subscale scores, previously transformed to a 0–100 scale according to the respective scoring procedures, were summarised using means and standard deviations at baseline and after the intervention. Functional, global health status, and symptom-related dimensions were analysed individually, without aggregation into a total score, as the questionnaire dimensions represent distinct constructs.

The distribution of continuous variables was assessed using the Shapiro–Wilk test. Changes between baseline and post-intervention assessments were analysed using paired samples t-tests when the normality assumption was met and Wilcoxon signed-rank tests when it was not. Associations between changes in study outcomes and continuous clinical or sociodemographic variables were explored using Pearson’s or Spearman’s correlation coefficients, depending on the distribution of the variables. These analyses were limited to age and time since mastectomy. Partner status was not included in inferential analyses because of the limited variability in the sample, with only two participants reporting no stable partner, and was therefore considered only descriptively.

In addition to statistical significance, the magnitude of changes was interpreted according to established EORTC criteria: changes of 1–10 points were considered small but perceptible, changes of 10–20 points were considered moderate and clinically relevant, and changes greater than 20 points were considered large and clinically meaningful. These thresholds were applied separately to each subscale, without calculating global scores, because the EORTC QLQ-C30 and QLQ-BR42 dimensions represent independent constructs.

The analyses considered the dimensions most directly related to the study objectives, including global health status, emotional functioning, social functioning, body image, sexual function, sexual enjoyment, and sexual activity problems.

Qualitative analysis

Qualitative data were analysed using thematic analysis following the framework proposed by Braun and Clarke [22, 23]. The initial coding was conducted by Marina Gómez-Esteban, first author of the study. Ana Belén Rivas-Paterna subsequently conducted a systematic review of the codes and emerging themes. The two researchers discussed the coding framework and thematic interpretation, and differences in interpretation were resolved through discussion and consensus.

The analysis involved familiarisation with the data through repeated and in-depth reading of all questionnaire responses, generation of initial codes, organisation of codes into broader themes, review and refinement of the themes, and their final definition and naming. Coding was informed by the study objectives and questionnaire structure while allowing themes to emerge inductively from participants’ responses. The analytical process involved continuous comparison between codes, themes, and the original responses.

Taguette, an open-source qualitative data analysis tool, was used to support the organisation and management of the qualitative data [24]. Two broad conceptual domains derived from the study objectives—personal experiences with nipple–areola complex micropigmentation and perceived barriers to access—were used to structure the initial interpretation without constraining the inductive development of themes.

All 18 participants who completed the intervention and the post-intervention questionnaire were included in the qualitative analysis. Saturation was considered to have been reached when participants’ responses began to repeat previously identified content and no new relevant themes emerged.

Sample size calculation

The sample size was calculated for a paired pre–post comparison, assuming a clinically relevant within-participant change of 14 points in the EORTC QLQ-C30, based on minimally important difference estimates reported in breast cancer populations [15]. A standard deviation of 20 points was assumed based on the variability reported for EORTC QLQ-C30 scores in breast cancer populations [16]. A two-sided significance level of α = 0.05 and a statistical power of 80% were assumed. Using the formula n=(Zα/2+Zβ)×σΔ2, the required sample size was estimated at 16 participants. To account for an anticipated 30% loss to follow-up, the target sample size was increased to 23 participants. This allowance was included as a pragmatic precaution, given that substantial attrition has been reported in prospective oncology studies, with clinical deterioration and loss to follow-up among the documented reasons for dropout [17].

Ethical considerations

The study was approved by the Clinical Research Ethics Committee of the Hospital Clínico San Carlos. All participants received detailed information about the study and signed informed consent prior to inclusion.

Data were pseudonymised using alphanumeric codes and treated confidentially. Storage was securely maintained in physical and digital formats through the REDCap platform, with restricted access to the research team. The study was conducted in accordance with the Declaration of Helsinki and applicable data protection regulations (GDPR and Spanish LOPDGDD). Participants’ right to withdraw at any time without consequences was guaranteed, and data will be stored for the period required by applicable regulations.

Results

Participant characteristics

A total of 19 women were initially included in the study; however, one participant was excluded due to incomplete post-intervention assessment, resulting in a final sample of 18 participants. The mean age was 56.8 years (SD = 8.3), ranging from 42 to 68 years, and the time since mastectomy ranged from 1 to 23 years, with a mean of 4.5 years (SD = 5.3). Most participants had a stable partner (n = 16, 88.9%), while 11.1% (n = 2) did not have a stable partner.

Quantitative results

Changes in health-related quality of life, body image, emotional functioning, and sexual outcomes were assessed using the EORTC QLQ-C30 and QLQ-BR42 questionnaires. Full descriptive statistics for all subscales at baseline and post-intervention are presented in Table 1.

Table 1.

Descriptive statistics and pre–post intervention comparison of EORTC QLQ-C30 and QLQ-BR42 subscales

EORTC QLQ-C30 and QLQ-BR42
Pre-micropigmentation Post-micropigmentation
Subscales Mean Standard deviation Mean Standard deviation P-value
Functional subscales Physical function 15.2 14.1 11.1 12.9 0.05
Emotional function 25.5 23.8 9.7 14.4 0.00
Social function 25.9 28.1 17.6 27.7 0.24
Concern about the future 55.6 44.3 35.2 33.3 0.01
Overall health 63.0 19.6 78.2 13.8 0.00
Body image 44.4 36.9 22.2 28.4 0.00
Sexual function 25.9 24.4 42.6 27.6 0.01
Sexual satisfaction 29.6 22.6 38.9 28.6 0.01
Problems with sexual activity 25.9 24.4 42.6 27.6 0.01
Symptom subscales Breast symptoms 10.7 14.5 12.5 15.5 0.71
Arm symptoms 26.5 23.2 19.8 22.4 0.05
Hormonal symptoms 35.2 33.3 22.2 32.3 0.06
Systemic treatment side effects 26.5 16.1 18.8 15.4 0.00

Score interpretation depends on the direction of each scale: for functional and global health scales, higher scores indicate better functioning, whereas for symptom scales, higher scores indicate greater symptom burden; the direction of each BR42 subscale was interpreted according to its scoring specification.

Overall, a clear improvement in global health status was observed after the intervention, with mean scores increasing from 63.0 (SD = 19.6) at baseline to 78.24 (SD = 13.8) post-intervention (p < 0.05), indicating improved perceived quality of life. Emotional functioning also showed a relevant improvement, with scores decreasing from 25.5 (SD = 23.8) to 9.7 (SD = 14.4) post-intervention (p < 0.05), reflecting better emotional status.

Body image was one of the most relevant domains affected by the intervention, with scores decreasing from 44.4 (SD = 36.9) at baseline to 22.2 (SD = 28.4) after the intervention (p < 0.01). Given the direction of the EORTC QLQ-BR42 scale, this decrease indicates a reduction in body image–related distress and an improvement in body perception following nipple–areola complex micropigmentation.

Regarding sexual outcomes, improvements were also observed across the evaluated dimensions. Sexual activity problems, where higher scores indicate fewer difficulties, increased from 25.9 (SD = 24.4) to 42.6 (SD = 27.6) after the intervention. In parallel, sexual function and sexual enjoyment increased, suggesting an overall improvement in sexual well-being, as detailed in Table 1.

No statistically significant associations were identified between age and time since mastectomy and the clinical outcomes evaluated (Table 2). Time since mastectomy showed nonsignificant positive trends with emotional functioning (r = 0.453; p = 0.060) and body image (r = 0.420; p = 0.083).

Table 2.

Association between sociodemographic variables and clinical outcomes

EORTC QLQ-C30 and QLQ-BR42
Age Time since mastectomy
Subscales P-value
Functional subscales Physical function 0.18 0.67
Emotional function 0.80 0.06
Social function 0.09 0.75
Concern about the future 0.58 0.15
Overall health 0.55 0.99
Body image 0.39 0.08
Sexual function 0.39 0.28
Sexual satisfaction 0.08 0.44
Problems with sexual activity 0.39 0.28
Symptom subscales Breast symptoms 0.31 0.89
Arm symptoms 0.60 0.55
Hormonal symptoms 0.27 0.50
Systemic treatment side effects 0.74 0.53

Correlation analyses between clinical subscales are presented in Table 3. A strong and statistically significant positive correlation was observed between body image and emotional functioning (r = 0.763; p < 0.001), indicating that better body perception is associated with better emotional status. Significant associations were also observed between sexual function and sexual activity problems, as well as between other emotional, physical, and sexual dimensions, indicating interrelationships among the clinical domains evaluated.

Table 3.

Correlation matrix between EORTC QLQ-C30 and QLQ-BR42 subscales

Physical function Emotional function Social function Body image Sexual function Concern about the future Breast symptoms Arm symptoms Hormonal symptoms Problems with sexual activity
Physical function 0.16 0.53 0.38 0.54 0.55 0.54 0.58 0.05 0.54
Emotional function 0.16 0.41 0.00 0.99 0.11 0.67 0.22 0.00 0.99
Social function 0.53 0.41 0.81 0.39 0.55 0.79 0.52 0.25 0.39
Body image 0.38 0.00 0.81 0.84 0.04 0.37 0.61 0.07 0.84
Sexual function 0.54 0.99 0.39 0.84 0.96 0.01 0.18 0.22 0.00
Concern about the future 0.55 0.11 0.55 0.04 0.96 0.40 0.76 0.47 0.96
Breast symptoms 0.54 0.67 0.79 0.37 0.01 0.40 0.04 0.20 0.01
Arm symptoms 0.58 0.22 0.52 0.61 0.18 0.76 0.04 0.18 0.18
Hormonal symptoms 0.05 0.00 0.25 0.07 0.22 0.47 0.20 0.18 0.22
Problems with sexual activity 0.54 0.99 0.39 0.84 0.00 0.96 0.01 0.18 0.22

Clinically meaningful changes were classified according to the predefined EORTC criteria: changes of 1–10 points were considered small but perceptible, changes of 10–20 points were considered moderate and clinically relevant, and changes greater than 20 points were considered large and clinically meaningful. These results are presented in Table 4.

Table 4.

Clinically meaningful changes in quality of life and sexual outcomes according to EORTC thresholds

EORTC QLQ-C30 and QLQ-BR42
Small Moderate Large
Subscales Frequency % Frequency % Frequency %
Functional subscales Physical function 5 27.8 3 16.7 0 0
Emotional function 4 22.2 1 5.6 6 33.3
Social function 0 0 1 5.6 4 22.2
Concern about the future 0 0 4 22.2 8 44.4
Overall health 2 11.1 4 22.2 6 33.3
Body image 0 0 4 22.2 8 44.4
Sexual function 0 0 0 0 7 38.9
Sexual satisfaction 0 0 3 16.7 3 16.7
Problems with sexual activity 0 0 0 0 7 38.9
Symptom subscales Breast symptoms 2 11.1 0 0 0 0
Arm symptoms 0 0 3 16.7 3 16.7
Hormonal symptoms 0 0 0 0 4 22.2
Systemic treatment side effects 8 44.4 3 16.7 2 11.1

In the body image domain, 44.4% (n = 8) of participants showed a large clinically relevant improvement and 22.2% (n = 4) a moderate improvement. In emotional functioning, 33.3% (n = 6) showed a large improvement, 5.6% (n = 1) a moderate improvement, and 22.2% (n = 4) a small improvement. In sexual enjoyment, 16.7% (n = 3) reported a large improvement and 16.7% (n = 3) a moderate improvement. Finally, in global health status, 33.3% (n = 6) showed a large improvement, 22.2% (n = 4) a moderate improvement, and 11.1% (n = 2) a small improvement.

Qualitative findings

The qualitative analysis included all study participants (n = 18). Two main themes were identified: personal experiences related to nipple–areola complex micropigmentation and perceived barriers to access.

Theme 1: Personal and psychosocial experiences following nipple–areola complex micropigmentation

This theme reflects participants’ subjective experience of the procedure, including motivations, lived experience of the process, and its impact on body identity, emotional well-being, and sexuality.

Participants described micropigmentation as a meaningful stage within the breast reconstruction process, associated with the recovery of body identity and a sense of closure of the cancer journey. In this sense, a strong symbolic component was identified, expressed in terms such as “feeling complete” (P03) or “closing a stage” (P12).

Regarding the experience of the procedure, participants reported initial emotions of uncertainty and fear, mainly related to aesthetic outcomes and perceived pain. However, the post-procedure experience was predominantly described as positive, highlighting professional support and a perceived safe environment. One participant stated: “I was afraid at the beginning, but then I felt very supported” (P07). In the post-procedure phase, satisfaction with the outcome predominated, with expressions such as “it exceeded my expectations” (P10).

In terms of quality of life impact, participants reported improvements in emotional well-being and social reintegration, reflected in the resumption of previously avoided activities such as wearing certain clothing or participating in leisure activities. Some participants stated: “I went back to the beach” (P17) or “I feel more confident with my body” (P05).

Changes in body self-image were one of the most relevant aspects, with improvements in perceived femininity, body integrity, and personal security. This process was described as a reconstruction of body identity, reflected in expressions such as “I feel more like myself” (P14).

Regarding sexuality, participants reported greater comfort and confidence during intimacy, contributing to improved confidence in partner relationships. One participant noted: “I feel more comfortable with my partner now” (P10).

Theme 2: Perceived barriers to access to micropigmentation

This theme captures participants’ perceived difficulties in accessing the procedure, including structural, informational, and emotional barriers, as well as suggestions for improvement.

The main barriers identified were lack of systematic information about micropigmentation within the breast reconstruction pathway, as well as unequal access depending on the healthcare centre. Several participants reported not having been informed about this option during their care process, as illustrated by the following quote: “no one informed me about this option” (P11).

Economic and geographical barriers were also identified, related to the limited availability of the procedure, the cost of accessing it in the private sector, and the need to travel to other centres. One participant described how the cost of the procedure had prevented her from completing the reconstructive process for several years: “I would also like to mention that I had had the reconstruction since 2018, but I did not complete the process because of the cost in the private sector; I could not afford it. I had already decided not to have it done and, after so much time, I thought it was not that important to me. But after having the procedure, I feel very proud and satisfied that I made the decision and with the results obtained” (P10).

This account illustrates how financial barriers may contribute to prolonged delays in completing the reconstructive process and how the perceived importance of nipple–areola complex restoration may change after access to the procedure.

At an emotional level, barriers included fear of pain, uncertainty about outcomes, and concerns about unmet expectations.

Despite these difficulties, the overall evaluation of the procedure was positive, and most participants would recommend it to other women in similar situations, highlighting its impact on emotional well-being and body identity reconstruction: “I would recommend it without hesitation” (P04).

Overall, the quantitative and qualitative findings showed convergence in the direction of the observed changes, while the qualitative findings provided contextualisation and deeper insight into participants’ subjective and experiential perspectives.

Discussion

The findings of this mixed-methods study provide complementary evidence regarding women’s experiences following nipple–areola complex (NAC) micropigmentation after mastectomy and breast reconstruction. The quantitative findings showed changes in several patient-reported outcomes, particularly in global health status, body image, and sexual dimensions, while the qualitative findings provided insight into the personal meaning attributed to the procedure and the barriers experienced when accessing it. These findings should be interpreted within the context of the single-group pre–post design, which does not allow causal inference regarding the observed changes.

Body image provides an important context for interpreting these findings. Breast cancer treatment and mastectomy may substantially affect women’s perceptions of their bodies, sexuality, femininity, and psychosocial adaptation, with body image concerns potentially persisting after completion of primary treatment [5–9]. Breast reconstruction may contribute to physical and psychosocial recovery, but the restoration of the NAC can represent a further stage in the reconstructive process by contributing to the visual completion of the reconstructed breast [10–13, 25–27]. In the present study, body image showed one of the most pronounced changes observed, and participants described the procedure in terms of recovering body identity, femininity, and a sense of bodily integrity. These qualitative accounts are consistent with previous evidence suggesting that NAC reconstruction may have psychosocial relevance beyond the technical restoration of the breast [10, 11]. Nevertheless, the observed changes cannot be interpreted as demonstrating that micropigmentation itself caused the improvement.

The qualitative findings further indicate that the perceived value of NAC micropigmentation extended beyond the visual outcome of the procedure. Participants described the intervention as a meaningful stage within their reconstructive trajectory and associated it with a sense of completion and recovery of a more familiar body image. Previous studies have similarly reported high levels of patient satisfaction and psychosocial benefits following NAC reconstruction and dermopigmentation [10, 11]. Evidence remains heterogeneous, however, with differences in techniques, timing, outcome measures, and study designs across the available literature [12, 13]. The mixed-methods approach used in the present study therefore provides complementary information by combining patient-reported outcomes with participants’ descriptions of the personal and emotional meaning of NAC restoration.

Sexuality is another relevant dimension of recovery after breast cancer treatment. Changes in body image, femininity, self-confidence, and intimate relationships may influence sexual functioning and sexual well-being after mastectomy [7–9]. In the present study, changes were observed across several sexual dimensions, while participants described greater comfort and confidence in intimate situations. These findings provide a broader context for understanding sexuality as part of post-mastectomy adaptation rather than as an isolated outcome. Previous research on NAC reconstruction has also reported associations between reconstruction of the NAC and patient-reported satisfaction and broader breast-related outcomes [28, 29]. Nevertheless, the uncontrolled design of the present study prevents determining whether the observed changes in sexual outcomes were attributable specifically to micropigmentation.

An important contribution of the qualitative findings concerns barriers to accessing NAC micropigmentation. Participants described difficulties related to insufficient information about the procedure, differences in availability between healthcare centres, geographical displacement, economic burden, and concerns regarding pain or the expected aesthetic result. These findings suggest that, from participants’ perspectives, access may be influenced not only by whether the procedure is technically available but also by whether women receive timely information and have a clear pathway through which they can obtain it. The absence of systematic information may be particularly relevant because patients may not independently identify NAC micropigmentation as a possible component of their reconstructive care.

Geographical and organisational barriers may further contribute to unequal access. When NAC micropigmentation is available only in selected centres, patients may need to travel to another location, generating additional logistical and financial demands. More broadly, recent literature on equity in breast cancer care highlights the importance of considering socioeconomic, geographical, organisational, and health literacy factors when designing patient-centred models of care [30]. In this context, equitable access to NAC reconstruction requires consideration not only of service availability but also of the mechanisms through which patients are informed, referred, and supported in navigating the healthcare system.

Emotional barriers should also be considered within the access pathway. Fear of pain, uncertainty regarding the final aesthetic result, and concerns about unmet expectations may influence whether women accept or pursue the procedure. Clear information about the procedure, expected outcomes, potential discomfort, and available support may therefore facilitate informed decision-making. From this perspective, access should be understood as a multidimensional process involving availability, information, referral, professional support, and the patient’s ability to navigate the pathway.

These findings may support consideration of NAC micropigmentation within coordinated clinical pathways rather than as an isolated procedure. Recent evidence from the ARCADE_M mixed-methods study describes a nurse-led NAC tattooing clinic as a feasible complex intervention and highlights the importance of professional competence, training, coordination, resources, and organisational sustainability for implementation [31]. Such models provide a relevant framework for considering how NAC micropigmentation may be incorporated into breast cancer care. Within a coordinated pathway, nurses may contribute to patient education, preparation for the procedure, identification of informational and emotional needs, coordination with other professionals, and continuity of care.

From an equity perspective, patients should not be expected to identify the procedure independently, locate a specialised provider, or travel to another centre without appropriate information and professional guidance. Systematic information provision and transparent referral pathways may help reduce avoidable differences in access, particularly where specialised services are not uniformly available. Patient and public involvement approaches may also contribute to the design of breast cancer care pathways that better reflect patients’ informational needs and experiences of navigating healthcare services [30]. Incorporating patient perspectives into pathway development may therefore help identify barriers that are not readily apparent from an exclusively clinical or organisational perspective.

This study has several strengths. The mixed-methods design allowed quantitative changes in patient-reported outcomes to be considered alongside participants’ subjective experiences and perceptions of access. The use of breast cancer-specific validated patient-reported outcome measures provided a structured assessment of relevant quality-of-life and sexual dimensions, while the qualitative analysis contributed contextual information that could not be captured through questionnaires alone. In addition, the qualitative analysis involved an initial coding process followed by systematic review and discussion of codes and themes between two researchers, with differences resolved through consensus.

Several limitations should be considered. The study used a single-group pre–post design without a control group, which limits causal inference and means that the observed changes cannot be attributed exclusively to NAC micropigmentation. Changes may also reflect other factors occurring during the period between assessments, including ongoing recovery, adaptation, or other aspects of post-treatment care. Furthermore, the final sample was relatively small and did not reach the calculated target of 23 participants, which may have limited the statistical power to detect smaller changes or associations. In addition, participants were recruited from a single clinical setting, which may limit the generalisability of the findings to other populations and healthcare contexts.

Another consideration concerns the timing of NAC micropigmentation. Although time since mastectomy was collected as a continuous clinical variable and ranged from 1 to 23 years, the study did not systematically collect or analyse the interval between breast reconstruction and NAC micropigmentation or the timing of micropigmentation in relation to other stages of the reconstructive pathway. Consequently, the potential influence of the timing of the procedure on patient-reported outcomes could not be assessed. The observed variability in time since mastectomy should therefore be considered when interpreting the findings, as participants may have differed in their stage of physical and emotional adaptation before micropigmentation.

With regard to the qualitative component, although the analysis involved discussion and consensus between two researchers, no formal inter-coder reliability statistic was calculated. Finally, longer-term follow-up was not available, limiting conclusions regarding the persistence of the observed changes.

Future research should therefore include larger prospective studies with longer follow-up and, where feasible, comparator groups or controlled designs. Further studies should examine whether the timing of NAC micropigmentation within the reconstructive pathway influences patient-reported outcomes and should evaluate structured information and referral strategies. Research should also assess nurse-led and multidisciplinary models of care, including professional training, organisational feasibility, patient experience, and equity of access. Such work could contribute to the development of coordinated and patient-centred pathways for NAC restoration within comprehensive breast cancer survivorship care.

Conclusion

Following nipple–areola complex micropigmentation, changes were observed in quality of life, body image, and sexual well-being among women who had undergone mastectomy and breast reconstruction. Quantitative and qualitative findings showed broadly convergent patterns, with participants describing improvements in body perception, emotional well-being, and confidence in intimate and social contexts. However, given the uncontrolled single-group pre–post design, these findings cannot establish a causal effect of micropigmentation.

The qualitative findings also identified informational, geographical, economic, and emotional barriers to accessing the procedure. These findings highlight the importance of timely information, appropriate referral, and coordinated care within the breast reconstruction pathway. Further research using larger samples, comparative designs, longer follow-up, and more diverse populations is needed to strengthen the evidence regarding the effectiveness and longer-term impact of nipple–areola complex micropigmentation and to evaluate strategies for its equitable integration into clinical practice.

Author contributions

Marina Gómez-Esteban (M.G.-E.) conceived and designed the study, coordinated the research, and drafted the manuscript. Carla Pérez-Ingidua (C.P.-I.), Paula López-Porras (P.L.-P.), Ana Ascaso-del-Río (A.A.-R.), Verónica Gimeno-Hernán (V.G.-H.), and Ana Belén Rivas-Paterna (A.B.R.-P.) contributed to data collection and interpretation and data analysis. Ana Belén Rivas-Paterna (A.B.R.-P.) also critically revised the manuscript and approved the final version.

Funding

This research received no specific grant from any public funding agency, commercial entity, or private company.

Data availability

The datasets generated and/or analysed during the current study are not publicly available due to privacy and ethical restrictions but are available from the corresponding author on reasonable request.

Declarations

Ethical approval

The study was approved by the Clinical Research Ethics Committee of Hospital Clínico San Carlos. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare no competing interests.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.World Health Organization (2022) Breast cancer fact sheet [Internet]. WHO, Geneva. https://www.who.int/es/news-room/fact-sheets/detail/breast-cancer. Accessed 1 May 2026
  • 2.Sociedad Española de Oncología Médica (SEOM) (2024) Las cifras del cáncer en España 2024. SEOM, Madrid. https://www.seom.org/images/LAS_CIFRAS_2024.pdf. Accessed 1 May 2026
  • 3.Pérez García A et al (2019) Global survival of breast cancer patients. Rev Senol Patol Mamar 32(1):24–31. 10.1016/j.senol.2019.05.002 [DOI] [Google Scholar]
  • 4.American Cancer Society (2024) Breast cancer survival rates [Internet]. American Cancer Society, Atlanta. https://www.cancer.org/es/cancer/tipos/cancer-de-seno/comprension-de-un-diagnostico-de-cancer-de-seno/tasas-de-supervivencia-del-cancer-de-seno.html. Accessed 1 May 2026
  • 5.Afshar-Bakshloo M, Albers S, Richter C, Berninger O, Blohmer JU, Roehle R et al (2023) How breast cancer therapies impact body image: real-world data from a prospective cohort study collecting patient-reported outcomes. BMC Cancer 23(1):705. 10.1186/s12885-023-11172-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Hong W, She Z, Liu X, Yang P (2025) A comparative study of quality of life and psychosocial adaptability following modified radical mastectomy and breast reconstruction. Sci Rep 15:45382. 10.1038/s41598-025-29121-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Juarez-Gómez J, Cantero-Garlito PA (2026) Body image, sexuality and coping in women surviving breast cancer: a phenomenological qualitative study. Sexes 7(1):9. 10.3390/sexes7010009 [DOI] [Google Scholar]
  • 8.Saruhan Ç, Özkan M (2025) The effect of psychoeducation on body image and sexual quality of life in patients undergoing mastectomy: a randomized controlled trial. Eur J Oncol Nurs 79:103001. 10.1016/j.ejon.2025.103001 [DOI] [PubMed] [Google Scholar]
  • 9.Cairo Notari S et al (2024) Changes in sexuality after breast cancer surgery: a longitudinal study. Sex Disabil. 10.1007/s11195-024-09854-x [DOI] [Google Scholar]
  • 10.Padullés-Escarré A, López-Ojeda A, Sánchez-Egea A et al (2024) Grado de satisfacción de las mujeres tratadas con reconstrucción y dermopigmentación del complejo aréola-pezón tras la reconstrucción mamaria. Enferm Clin 34(2):82–89. 10.1016/j.enfcle.2024.03.002 [DOI] [PubMed] [Google Scholar]
  • 11.Aizpiolea-Martínez P, Casamayor-Franco C, Lahuerta-Lorente L, Hernando-Almudi E, Dobato-Portolés O (2026) Areola-nipple complex micropigmentation in breast reconstruction: patient perspective and psychosocial benefits. Rev Senol Patol Mamar 39(2):100749 [Google Scholar]
  • 12.Maselli D, Torreggiani M, Livieri T, Guberti M et al (2024) Tattooing to reconstruct nipple–areola complex after oncological breast surgery: a scoping review. Support Care Cancer 32:153. 10.1007/s00520-024-08351-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Maselli D, Torreggiani M, Soffientini V, Tamagnini E, Botti S, Ferri P et al (2026) The role of nipple–areola complex tattooing in breast cancer psycho-physical rehabilitation: an updated review. Cancer Treat Res Commun 46:101075. 10.1016/j.ctarc.2025.101075 [DOI] [PubMed] [Google Scholar]
  • 14.Polita BSD, Lapinš J, Ģīlis A, Grucki M, Irmejs A, Gardovskis J, Maksimenko J (2024) Evaluation of breast skin/nipple–areolar complex sensation and quality of life after nipple-sparing mastectomy followed by reconstruction. Medicina (Kaunas) 60(10):1655. 10.3390/medicina60101655 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Mierzynska J, Taye M, Pe M et al (2020) Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. Eur J Cancer 125:69–82. 10.1016/j.ejca.2019.10.031 [DOI] [PubMed] [Google Scholar]
  • 16.Musoro JZ, Coens C, Fiteni F et al (2019) Minimally important differences for interpreting EORTC QLQ-C30 change scores in patients with advanced breast cancer. JNCI Cancer Spectr 3(3):pkz037. 10.1093/jncics/pkz037 [DOI] [PMC free article] [PubMed]
  • 17.Hui D, Glitza I, Chisholm G, Yennu S, Bruera E (2013) Attrition rates and associated factors in supportive and palliative oncology trials. Cancer 119(7):1448–1454. 10.1002/cncr.27854 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376. 10.1093/jnci/85.5.365 [DOI] [PubMed] [Google Scholar]
  • 19.Bjelic-Radisic V, Cardoso F, Weis J, Pogoda K, Arraras JI, Greimel E et al (2025) EORTC Quality of Life Group and Breast Cancer Group. An international Phase IV field study - psychometric properties of the updated module on assessing quality of life of patients with breast cancer EORTC QLQ-BR42. Breast. 80:103890. 10.1016/j.breast.2025.103890 [DOI] [PMC free article] [PubMed]
  • 20.Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) The EORTC QLQ-C30 scoring manual, 3rd ed. European Organisation for Research and Treatment of Cancer (EORTC), Brussels [Google Scholar]
  • 21.IBM Corp (2022) IBM SPSS statistics for Windows, version 29.0. IBM Corp, Armonk, NY [Google Scholar]
  • 22.Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3(2):77–101. 10.1191/1478088706qp063oa [DOI] [Google Scholar]
  • 23.Nowell LS, Norris JM, White DE, Moules NJ (2017) Thematic analysis: striving to meet the trustworthiness criteria. Int J Qual Methods 16:1–13. 10.1177/1609406917733847 [DOI] [Google Scholar]
  • 24.Rampin R, Rampin V, Aparicio S, Reider N, Fard D (2021) Taguette: open-source qualitative data analysis tool. J Open Source Softw 6(68):3384. 10.21105/joss.03384 [DOI] [Google Scholar]
  • 25.González-López E, Marzo-Martínez A, Saceda-Legaz O, Sáez-Gómez N, Osorio-Álvarez S, Oltra-Rodríguez E (2021) Micropigmentación de areola y pezón dentro de la atención integral de la mujer mastectomizada [Internet]. Zenodo.  [cited 2026 May 9]. 10.5281/zenodo.5810700 [DOI]
  • 26.Uhlmann NR, Martins MM, Piato S (2019) 3D areola dermopigmentation (nipple-areola complex). Breast J 25(6):1214–1221. 10.1111/tbj.13427 [DOI] [PubMed] [Google Scholar]
  • 27.Rice M, Colavitti G, Jackson P, Wilson S (2024) Nipple–areola complex reconstruction: an 8-year experience with modified technique and systematic review. Eplasty 24:e36 [PMC free article] [PubMed] [Google Scholar]
  • 28.Graziano FD, Levy J, Kim M, Massand S, Shammas RL, Boe L et al (2026) Effect of nipple–areola complex reconstruction on BREAST-Q outcomes after implant-based breast reconstruction. Plast Reconstr Surg 157(3):420–427. 10.1097/PRS.0000000000012388 [DOI] [PubMed] [Google Scholar]
  • 29.Jones A, Giles C, Davis E, Bruce C, Costigan N, Boe LA et al (2026) Patient preferences and satisfaction of nipple areola reconstruction with three-dimensional tattoo in the setting of bilateral implant-based breast reconstruction. Plast Surg (Oakv) 34(1):17–22. 10.1177/22925503241303513 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Maselli D, Costi S (2026) Advancing equity in breast cancer care through patient and public involvement and engagement. Cancer Control 33:10732748261460119. 10.1177/10732748261460119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Maselli D, Torreggiani M, Soffientini V, Livieri T, Farioli G, Lucchi S et al (2026) The feasibility of a complex intervention, a medical tattooing nurse-led clinic after breast cancer surgery: results from the ARCADE_M mixed-methods study. Sci Rep 16:1877. 10.1038/s41598-025-31551-8 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets generated and/or analysed during the current study are not publicly available due to privacy and ethical restrictions but are available from the corresponding author on reasonable request.


Articles from Supportive Care in Cancer are provided here courtesy of Springer

RESOURCES